| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2404660 | Vaccine | 2009 | 8 Pages |
Abstract
Priorix-Tetra™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix™) and varicella (Varilrix™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Hanna Czajka, Volker Schuster, Fred Zepp, Susanna Esposito, Martine Douha, Paul Willems,